ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Bristol-Myers Squibb and AbbVie side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Bristol-Myers SquibbAbbVie
studies on the registry2,1842,251
open to participants now155133
phase 3 studies under way8274
reach primary completion within a year6790
programswith a study of their own in two years57+9 named only70+8 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseBristol-Myers SquibbAbbVie
Phase 1

Bristol-Myers Squibb: 17 of its 57 programs at phase 1

  1. BMS-986454phase 1
  2. orevandrodegphase 1
  3. Actinium Ac 225 SSTR2-targeted Agent RYZ401phase 1
  4. BMS-985521phase 1
  5. BMS-986485phase 1

and 12 more — sign in to see them all

30%

AbbVie: 28 of its 70 programs at phase 1

  1. Anti-CD19-Glucosteroid Receptor Modulator ADC ABBV-31phase 1
  2. surzetoclaxphase 1
  3. BTK Degrader ABBV-101phase 1
  4. ABBV-1162phase 1
  5. ABBV-1451phase 1

and 23 more — sign in to see them all

40%
Phase 2

Bristol-Myers Squibb: 17 of its 57 programs at phase 2

  1. irafamdastatphase 2
  2. moponetugphase 2
  3. delocamtenphase 2
  4. imzokitugphase 2
  5. Cyclophosphamidephase 2

and 12 more — sign in to see them all

30%

AbbVie: 20 of its 70 programs at phase 2

  1. ABBV-295phase 2
  2. zumilokibartphase 2
  3. ABBV-932phase 2
  4. trosunilimabphase 2
  5. ABBV-701phase 2

and 15 more — sign in to see them all

29%
Phase 3

Bristol-Myers Squibb: 16 of its 57 programs at phase 3

  1. navlimetostatphase 3
  2. pumitamigphase 3
  3. adagrasibphase 3
  4. golcadomidephase 3
  5. zolacabtagene autoleucelphase 3

and 11 more — sign in to see them all

28%

AbbVie: 16 of its 70 programs at phase 3

  1. telisotuzumab adizutecanphase 3
  2. etentamigphase 3
  3. lutikizumabphase 3
  4. mirvetuximab soravtansinephase 3
  5. turmetabart adizutecanphase 3

and 11 more — sign in to see them all

23%
Approved, new studies

Bristol-Myers Squibb: 7 of its 57 programs at approved, new studies

  1. xanomelineapproved, new study
  2. trospiumapproved, new study
  3. deucravacitinibapproved, new study
  4. Nivolumabapproved, new study
  5. trospium chlorideapproved, new study

and 2 more — sign in to see them all

12%

AbbVie: 6 of its 70 programs at approved, new studies

  1. upadacitinibapproved, new study
  2. risankizumabapproved, new study
  3. venetoclaxapproved, new study
  4. botulinum toxin type Aapproved, new study
  5. atogepantapproved, new study

and 1 more — sign in to see them all

9%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Bristol-Myers Squibb22 readouts · 7 phase 3

Bristol-Myers Squibb, Nov ’26: 2 programs whose next study reaches primary completion, 2 in phase 3

  1. trospiumapproved, new study · Nov 24 · NCT06585787
  2. xanomelineapproved, new study · Nov 24 · NCT06585787

Bristol-Myers Squibb, Dec ’26: 7 programs whose next study reaches primary completion, 1 in phase 3

  1. actinium AC-225 dotatatephase 3 · Dec 0 · NCT05477576
  2. navlimetostatphase 3 · Dec 5 · NCT07777133
  3. delocamtenphase 2 · Dec 14 · NCT06122779
  4. golcadomidephase 3 · Dec 14 · NCT07763418
  5. moponetugphase 2 · Dec 17 · NCT06268886

and 2 more — sign in to see them all

Bristol-Myers Squibb, Jan ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. mezigdomidephase 3 · Jan 10 · NCT05519085

Bristol-Myers Squibb, Feb ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. Actinium Ac 225 SSTR2-targeted Agent RYZ401phase 1 · Feb 0 · NCT07165132
  2. Nivolumabapproved, new study · Feb 5 · NCT06946797
  3. repotrectinibphase 3 · Feb 16 · NCT06140836

Bristol-Myers Squibb, Mar ’27: 1 program whose next study reaches primary completion

  1. trospium chlorideapproved, new study · Mar 29 · NCT07063342
·

Bristol-Myers Squibb, May ’27: 1 program whose next study reaches primary completion

  1. elranatamabphase 2 · May 31 · NCT06988488

Bristol-Myers Squibb, Jun ’27: 3 programs whose next study reaches primary completion

  1. BMS-986533phase 1 · Jun 1 · NCT07629999
  2. BMS-986485phase 1 · Jun 8 · NCT07887763
  3. BMS-986454phase 1 · Jun 28 · NCT07171983

Bristol-Myers Squibb, Jul ’27: 1 program whose next study reaches primary completion

  1. zolacabtagene autoleucelphase 3 · Jul 15 · NCT06220201

Bristol-Myers Squibb, Aug ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. atigotatugphase 3 · Aug 17 · NCT06646276

Bristol-Myers Squibb, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. dezandrodegphase 3 · Sep 12 · NCT06764485

Bristol-Myers Squibb, Oct ’27: 1 program whose next study reaches primary completion

  1. BMS-986488phase 1 · Oct 15 · NCT06764771
AbbVie34 readouts · 5 phase 3

AbbVie, Nov ’26: 6 programs whose next study reaches primary completion, 1 in phase 3

  1. ABBV-701phase 2 · Nov 0 · NCT06895343
  2. ABBV-932phase 2 · Nov 0 · NCT06846320
  3. mirvetuximab soravtansinephase 3 · Nov 0 · NCT05456685
  4. upadacitinibapproved, new study · Nov 0 · NCT06389136
  5. venetoclaxapproved, new study · Nov 0 · NCT04895436

and 1 more — sign in to see them all

AbbVie, Dec ’26: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. ABBV-295phase 2 · Dec 0 · NCT07514260
  2. emraclidinephase 2 · Dec 0 · NCT07219030
  3. lutikizumabphase 3 · Dec 0 · NCT06468228
  4. telisotuzumab adizutecanphase 3 · Dec 0 · NCT06107413

AbbVie, Jan ’27: 1 program whose next study reaches primary completion

  1. risankizumabapproved, new study · Jan 0 · NCT07466550

AbbVie, Feb ’27: 9 programs whose next study reaches primary completion

  1. [11C]ABBV-112iearly phase 1 · Feb 0 · NCT07933497
  2. ABBV-859phase 1 · Feb 0 · NCT07736638
  3. Anti-CD19-Glucosteroid Receptor Modulator ADC ABBV-31phase 1 · Feb 0 · NCT05512390
  4. etentamigphase 3 · Feb 0 · NCT06223516
  5. MEDI0618phase 2 · Feb 0 · NCT06602479

and 4 more — sign in to see them all

·

AbbVie, Apr ’27: 1 program whose next study reaches primary completion

  1. ABBV-1451phase 1 · Apr 0 · NCT07570147

AbbVie, May ’27: 6 programs whose next study reaches primary completion, 1 in phase 3

  1. ABBV-1162phase 1 · May 0 · NCT07832708
  2. ABBV-243phase 1 · May 0 · NCT07306754
  3. ABBV-7828phase 1 · May 0 · NCT07856706
  4. Anti-PSMA/STEAP1 Antibody-drug Conjugate ABBV-969phase 1 · May 0 · NCT06318273
  5. trosunilimabphase 2 · May 0 · NCT07925983

and 1 more — sign in to see them all

AbbVie, Jun ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. botulinum toxin type Aapproved, new study · Jun 0 · NCT07794891

AbbVie, Jul ’27: 4 programs whose next study reaches primary completion

  1. ABBV-1606phase 1 · Jul 0 · NCT07935564
  2. azirkitugphase 1 · Jul 0 · NCT05005403
  3. surzetoclaxphase 2 · Jul 0 · NCT06291220
  4. surzetoclaxphase 1 · Jul 0 · NCT06291220

AbbVie, Aug ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. vedolizumabphase 3 · Aug 0 · NCT06880744

AbbVie, Sep ’27: 1 program whose next study reaches primary completion

  1. icalcaprantphase 2 · Sep 0 · NCT07276997
·
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 23, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Bristol-Myers Squibb

New programs 5

  • BMS-986548phase 2 · first study · Nov 10
  • BMS-986485phase 1 · first study · Oct 14
  • BMS-986553phase 1 · first study · Oct 8 · Lupus Nephritis
  • RYZ711phase 2 · first study · Oct 1 · Prostatic Neoplasms
  • BMS-986527phase 1 · first study · Sep 22 · Carcinoma, Renal Cell

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

AbbVie

New programs 5

Reached a new phase 1

  • ABBV-722phase 3 · Oct 23 · Scleroderma, Systemic

Study stopped 0

None

Primary completion later 10

Where they overlap

Conditions where at least two of them have programs: 31 in all. A program counts in each condition its studies name most.

ConditionBristol-Myers SquibbAbbVie
Carcinoma, Non-Small-Cell Lungboth · compare here

Bristol-Myers Squibb in Carcinoma, Non-Small-Cell Lung: 11 programs

  1. navlimetostatphase 3
  2. pumitamigphase 3
  3. adagrasibphase 3
  4. izalontamab brengitecanphase 3
  5. repotrectinibphase 3

and 6 more — sign in to see them all

Their studies: Bristol-Myers Squibb’s studies of Carcinoma, Non-Small-Cell Lung in search

AbbVie in Carcinoma, Non-Small-Cell Lung: 4 programs

  1. telisotuzumab adizutecanphase 3
  2. ABBV-1480phase 3
  3. azirkitugphase 1
  4. RC148no phase

Their studies: AbbVie’s studies of Carcinoma, Non-Small-Cell Lung in search

Multiple Myelomaboth · compare here

Bristol-Myers Squibb in Multiple Myeloma: 6 programs

  1. mezigdomidephase 3
  2. arlocabtagene autoleucelphase 3
  3. Cyclophosphamidephase 2
  4. elranatamabphase 2
  5. fludarabinephase 1

and 1 more — sign in to see them all

Their studies: Bristol-Myers Squibb’s studies of Multiple Myeloma in search

Alzheimer Diseaseboth · compare here

Bristol-Myers Squibb in Alzheimer Disease: 5 programs

  1. irafamdastatphase 2
  2. moponetugphase 2
  3. xanomelineapproved, new study
  4. trospiumapproved, new study
  5. trospium chlorideapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Alzheimer Disease in search

AbbVie in Alzheimer Disease: 3 programs

  1. emraclidinephase 2
  2. ABBV-1758phase 2
  3. ALIA-1758phase 1

Their studies: AbbVie’s studies of Alzheimer Disease in search

Arthritis, Rheumatoidboth · compare here

Bristol-Myers Squibb in Arthritis, Rheumatoid: 3 programs

  1. tocilizumabphase 3
  2. BMS-986528phase 2
  3. BMS-986454phase 1

Their studies: Bristol-Myers Squibb’s studies of Arthritis, Rheumatoid in search

AbbVie in Arthritis, Rheumatoid: 5 programs

  1. lutikizumabphase 3
  2. ABBV-722phase 3
  3. ravagalimabphase 2
  4. CPTX2309phase 1
  5. upadacitinibapproved, new study

Their studies: AbbVie’s studies of Arthritis, Rheumatoid in search

Crohn Diseaseboth · compare here

Bristol-Myers Squibb in Crohn Disease: 1 program

  1. deucravacitinibapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Crohn Disease in search

AbbVie in Crohn Disease: 7 programs

  1. lutikizumabphase 3
  2. vedolizumabphase 3
  3. trosunilimabphase 2
  4. ABBV-701phase 2
  5. ABBV-8736phase 2

and 2 more — sign in to see them all

Their studies: AbbVie’s studies of Crohn Disease in search

Neoplasmsboth · compare here

Bristol-Myers Squibb in Neoplasms: 5 programs

  1. repotrectinibphase 3
  2. BMS-986488phase 1
  3. BMS-986500phase 1
  4. Digoxinphase 1
  5. relatlimabapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Neoplasms in search

Small Cell Lung Carcinomaboth · compare here

Bristol-Myers Squibb in Small Cell Lung Carcinoma: 5 programs

  1. pumitamigphase 3
  2. izalontamab brengitecanphase 3
  3. atigotatugphase 3
  4. BMS-986525phase 2
  5. atigotatugphase 2

Their studies: Bristol-Myers Squibb’s studies of Small Cell Lung Carcinoma in search

Breast Neoplasmsboth · compare here

Bristol-Myers Squibb in Breast Neoplasms: 4 programs

  1. pumitamigphase 3
  2. izalontamab brengitecanphase 3
  3. actinium AC-225 dotatatephase 3
  4. Cyclophosphamidephase 2

Their studies: Bristol-Myers Squibb’s studies of Breast Neoplasms in search

AbbVie in Breast Neoplasms: 2 programs

  1. trifluridine tipiracil drug combinationphase 3
  2. RC148no phase

Their studies: AbbVie’s studies of Breast Neoplasms in search

Colorectal Neoplasmsboth · compare here

Bristol-Myers Squibb in Colorectal Neoplasms: 3 programs

  1. pumitamigphase 3
  2. adagrasibphase 3
  3. Nivolumabapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Colorectal Neoplasms in search

AbbVie in Colorectal Neoplasms: 3 programs

  1. telisotuzumab adizutecanphase 3
  2. trifluridine tipiracil drug combinationphase 3
  3. RC148no phase

Their studies: AbbVie’s studies of Colorectal Neoplasms in search

Leukemia, Lymphocytic, Chronic, B-Cellboth · compare here

Bristol-Myers Squibb in Leukemia, Lymphocytic, Chronic, B-Cell: 3 programs

  1. lisocabtagene maraleucelphase 3
  2. Cyclophosphamidephase 2
  3. fludarabinephase 1

Their studies: Bristol-Myers Squibb’s studies of Leukemia, Lymphocytic, Chronic, B-Cell in search

AbbVie in Leukemia, Lymphocytic, Chronic, B-Cell: 3 programs

  1. surzetoclaxphase 2
  2. surzetoclaxphase 1
  3. venetoclaxapproved, new study

Their studies: AbbVie’s studies of Leukemia, Lymphocytic, Chronic, B-Cell in search

Arthritis, Psoriaticboth · compare here

Bristol-Myers Squibb in Arthritis, Psoriatic: 1 program

  1. deucravacitinibapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Arthritis, Psoriatic in search

AbbVie in Arthritis, Psoriatic: 4 programs

  1. lutikizumabphase 3
  2. ABBV-701phase 2
  3. ABBV-547phase 2
  4. risankizumabapproved, new study

Their studies: AbbVie’s studies of Arthritis, Psoriatic in search

Carcinoma, Hepatocellularboth · compare here

Bristol-Myers Squibb in Carcinoma, Hepatocellular: 4 programs

  1. pumitamigphase 3
  2. Actinium Ac 225 GPC3-targeted Peptide RYZ801phase 2
  3. Nivolumabapproved, new study
  4. relatlimabapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Carcinoma, Hepatocellular in search

AbbVie in Carcinoma, Hepatocellular: 1 program

  1. telisotuzumab adizutecanphase 3

Their studies: AbbVie’s studies of Carcinoma, Hepatocellular in search

Colitis, Ulcerativeboth · compare here

Bristol-Myers Squibb in Colitis, Ulcerative: 1 program

  1. deucravacitinibapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Colitis, Ulcerative in search

AbbVie in Colitis, Ulcerative: 4 programs

  1. vedolizumabphase 3
  2. ravagalimabphase 2
  3. upadacitinibapproved, new study
  4. risankizumabapproved, new study

Their studies: AbbVie’s studies of Colitis, Ulcerative in search

Lupus Erythematosus, Systemicboth · compare here

Bristol-Myers Squibb in Lupus Erythematosus, Systemic: 3 programs

  1. zolacabtagene autoleucelphase 3
  2. obexelimabphase 3
  3. deucravacitinibapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Lupus Erythematosus, Systemic in search

AbbVie in Lupus Erythematosus, Systemic: 1 program

  1. ABBV-519phase 1

Their studies: AbbVie’s studies of Lupus Erythematosus, Systemic in search

Lymphoma, Non-Hodgkinboth · compare here

Bristol-Myers Squibb in Lymphoma, Non-Hodgkin: 3 programs

  1. golcadomidephase 3
  2. lisocabtagene maraleucelphase 3
  3. fludarabinephase 1

Their studies: Bristol-Myers Squibb’s studies of Lymphoma, Non-Hodgkin in search

AbbVie in Lymphoma, Non-Hodgkin: 1 program

  1. venetoclaxapproved, new study

Their studies: AbbVie’s studies of Lymphoma, Non-Hodgkin in search

Prostatic Neoplasmsboth · compare here

Bristol-Myers Squibb in Prostatic Neoplasms: 3 programs

  1. dezandrodegphase 3
  2. RYZ711phase 2
  3. orevandrodegphase 1

Their studies: Bristol-Myers Squibb’s studies of Prostatic Neoplasms in search

Psoriasisboth · compare here

Bristol-Myers Squibb in Psoriasis: 1 program

  1. deucravacitinibapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Psoriasis in search

AbbVie in Psoriasis: 3 programs

  1. ABBV-295phase 2
  2. ABBV-547phase 2
  3. risankizumabapproved, new study

Their studies: AbbVie’s studies of Psoriasis in search

Schizophreniaboth · compare here

Bristol-Myers Squibb in Schizophrenia: 3 programs

  1. xanomelineapproved, new study
  2. trospiumapproved, new study
  3. trospium chlorideapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Schizophrenia in search

AbbVie in Schizophrenia: 1 program

  1. emraclidinephase 2

Their studies: AbbVie’s studies of Schizophrenia in search

Anemia, Hemolytic, Autoimmuneboth · compare here

Bristol-Myers Squibb in Anemia, Hemolytic, Autoimmune: 2 programs

  1. zolacabtagene autoleucelphase 3
  2. obexelimabphase 3

Their studies: Bristol-Myers Squibb’s studies of Anemia, Hemolytic, Autoimmune in search

AbbVie in Anemia, Hemolytic, Autoimmune: 1 program

  1. pegcetacoplanphase 2

Their studies: AbbVie’s studies of Anemia, Hemolytic, Autoimmune in search

Bipolar Disorderboth · compare here

Bristol-Myers Squibb in Bipolar Disorder: 1 program

  1. Lithiumphase 1

Their studies: Bristol-Myers Squibb’s studies of Bipolar Disorder in search

AbbVie in Bipolar Disorder: 2 programs

  1. ABBV-932phase 2
  2. icalcaprantphase 2

Their studies: AbbVie’s studies of Bipolar Disorder in search

Depressive Disorder, Majorboth · compare here

Bristol-Myers Squibb in Depressive Disorder, Major: 1 program

  1. BMS-986511phase 2

Their studies: Bristol-Myers Squibb’s studies of Depressive Disorder, Major in search

AbbVie in Depressive Disorder, Major: 2 programs

  1. icalcaprantphase 2
  2. bretisilocinphase 2

Their studies: AbbVie’s studies of Depressive Disorder, Major in search

Lymphoma, Large B-Cell, Diffuseboth · compare here

Bristol-Myers Squibb in Lymphoma, Large B-Cell, Diffuse: 2 programs

  1. lisocabtagene maraleucelphase 3
  2. Cyclophosphamidephase 2

Their studies: Bristol-Myers Squibb’s studies of Lymphoma, Large B-Cell, Diffuse in search

Melanomaboth · compare here

Bristol-Myers Squibb in Melanoma: 2 programs

  1. Nivolumabapproved, new study
  2. relatlimabapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Melanoma in search

AbbVie in Melanoma: 1 program

  1. vedolizumabphase 3

Their studies: AbbVie’s studies of Melanoma in search

Scleroderma, Systemicboth · compare here

Bristol-Myers Squibb in Scleroderma, Systemic: 2 programs

  1. zolacabtagene autoleucelphase 3
  2. tocilizumabphase 3

Their studies: Bristol-Myers Squibb’s studies of Scleroderma, Systemic in search

AbbVie in Scleroderma, Systemic: 1 program

  1. ABBV-722phase 3

Their studies: AbbVie’s studies of Scleroderma, Systemic in search

Arthritis, Juvenileboth · compare here

Bristol-Myers Squibb in Arthritis, Juvenile: 1 program

  1. tocilizumabphase 3

Their studies: Bristol-Myers Squibb’s studies of Arthritis, Juvenile in search

AbbVie in Arthritis, Juvenile: 1 program

  1. risankizumabapproved, new study

Their studies: AbbVie’s studies of Arthritis, Juvenile in search

Idiopathic Pulmonary Fibrosisboth · compare here

Bristol-Myers Squibb in Idiopathic Pulmonary Fibrosis: 1 program

  1. admilparantphase 3

Their studies: Bristol-Myers Squibb’s studies of Idiopathic Pulmonary Fibrosis in search

AbbVie in Idiopathic Pulmonary Fibrosis: 1 program

  1. ABBV-142phase 2

Their studies: AbbVie’s studies of Idiopathic Pulmonary Fibrosis in search

Muscle Spasticityboth · compare here

Bristol-Myers Squibb in Muscle Spasticity: 1 program

  1. irafamdastatphase 2

Their studies: Bristol-Myers Squibb’s studies of Muscle Spasticity in search

AbbVie in Muscle Spasticity: 1 program

  1. botulinum toxin type Aapproved, new study

Their studies: AbbVie’s studies of Muscle Spasticity in search

Obesityboth · compare here

Bristol-Myers Squibb in Obesity: 1 program

  1. Digoxinphase 1

Their studies: Bristol-Myers Squibb’s studies of Obesity in search

AbbVie in Obesity: 1 program

  1. ABBV-295phase 2

Their studies: AbbVie’s studies of Obesity in search

Stomach Neoplasmsboth · compare here

Bristol-Myers Squibb in Stomach Neoplasms: 1 program

  1. relatlimabapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Stomach Neoplasms in search

AbbVie in Stomach Neoplasms: 1 program

  1. trifluridine tipiracil drug combinationphase 3

Their studies: AbbVie’s studies of Stomach Neoplasms in search

Strokeboth · compare here

Bristol-Myers Squibb in Stroke: 1 program

  1. milvexianphase 2

Their studies: Bristol-Myers Squibb’s studies of Stroke in search

AbbVie in Stroke: 1 program

  1. botulinum toxin type Aapproved, new study

Their studies: AbbVie’s studies of Stroke in search

Urinary Bladder, Overactiveboth · compare here

Bristol-Myers Squibb in Urinary Bladder, Overactive: 1 program

  1. trospium chlorideapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Urinary Bladder, Overactive in search

AbbVie in Urinary Bladder, Overactive: 1 program

  1. botulinum toxin type Aapproved, new study

Their studies: AbbVie’s studies of Urinary Bladder, Overactive in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: Bristol-Myers Squibb 32 of 57 · AbbVie 54 of 70 programs (28 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Bristol-Myers Squibb: 9, AbbVie: 8).